Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TAS-102 plus best supportive care versus placebo plus best supportive care in refractory metastatic gastric cancer
2015-002683-16Phase 3Completed
- Sponsor
- Taiho Oncology
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) comparing TAS-102 plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Started Sep 2015; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2015-002683-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002683-16.